Error loading player: No playable sources found
64248
Parallel Session 9: Genetic Characterization Technologies for Product Quality, Safety and Identity
Date
June 28, 2023
This product is not available for individual purchase, but it is available as part of the following products:
The Cell and Gene Therapy Products (CGTP) Symposium: Manufacturing, Quality and Regulatory Considerations enables the exchange of scientific ideas and dialogue with regulators that form the basis of evolving regulatory practices in the development of these diverse and innovative products…
The further advance of techniques for genetic modification also necessitates development of novel and more comprehensive genetic characterization tools to identify intended and unintended genetic changes in (subpopulations of) genetically modified cells. But the proliferation of these tools poses both opportunities and challenges for those developing cell and gene therapy products. The selection of global and/or targeted genomic analysis methods requires developers to consider the questions they wish to answer and the intended purposes behind the testing.
Is the analysis intended as a one-time highly-detailed survey of a gene-modified product, or will it be used for lot release testing? For viral vector products, what methods are best to confirm transgene identity and integrity? For gene-edited cells, how does one approach assessment of on-target versus off-target edits? For induced pluripotent stem cells (iPSCs), how does one detect genetic variants? What is the role for sequencing methods in testing of critical components and starting materials? How can bioinformatics tools be qualified in order to reliably use the large datasets generated by methods such as Next Generation Sequencing (NGS)? What are the strengths and limitations of the tools available to us, and how do more traditional methods such as karyotyping fit into the control strategy for cellular therapies?
In this session, we will explore the varied technologies available for genetic characterization and how they can be applied to ensure product quality and patient safety.
Session Speakers:
Characterization of VivoVec: A Surface-Engineered Lentiviral Vector Platform That Generates CAR T Cells in Vivo
Richard Rogers, Umoja Biopharma
Control of Chromosome Integrity in the Routine Manufacturing of Allogeneic CAR T Cell Therapies
Kimberly Davis, Sana Biotechnology
INDUCE-seq: Ensuring the Safe Development of Cell and Gene Therapies by Gene Editing
Simon Reed, Cardiff University
Additional Panelists:
Anna Kwilas, CBER, FDA
Is the analysis intended as a one-time highly-detailed survey of a gene-modified product, or will it be used for lot release testing? For viral vector products, what methods are best to confirm transgene identity and integrity? For gene-edited cells, how does one approach assessment of on-target versus off-target edits? For induced pluripotent stem cells (iPSCs), how does one detect genetic variants? What is the role for sequencing methods in testing of critical components and starting materials? How can bioinformatics tools be qualified in order to reliably use the large datasets generated by methods such as Next Generation Sequencing (NGS)? What are the strengths and limitations of the tools available to us, and how do more traditional methods such as karyotyping fit into the control strategy for cellular therapies?
In this session, we will explore the varied technologies available for genetic characterization and how they can be applied to ensure product quality and patient safety.
Session Speakers:
Characterization of VivoVec: A Surface-Engineered Lentiviral Vector Platform That Generates CAR T Cells in Vivo
Richard Rogers, Umoja Biopharma
Control of Chromosome Integrity in the Routine Manufacturing of Allogeneic CAR T Cell Therapies
Kimberly Davis, Sana Biotechnology
INDUCE-seq: Ensuring the Safe Development of Cell and Gene Therapies by Gene Editing
Simon Reed, Cardiff University
Additional Panelists:
Anna Kwilas, CBER, FDA
Session Chairs
General
Tracks
Related Products
Plenary Session 12: Updates in the Regulatory Landscape for Cell & Gene Therapy Products
Several cell and gene therapy products have received marketing approval from health authorities and, with that, a more complete picture is now emerging about the regulatory CMC requirements to commercialize these products…
Parallel Session 10: Platform Development Approaches for AAV Gene Therapy Products
With the recent approval of several Adeno-Associated Virus (AAV)-based gene therapies, the application of AAV gene therapy approaches to the treatment of human disease is expanding…
Keynote Presentation
Gene Therapy Drug Development for Ultra-Rare Disease: Challenges & Opportunities
